Activation of p53, inhibition of telomerase activity and induction of estrogen receptor beta are associated with the anti-growth effects of combination of ovarian hormones and retinoids in immortalized human mammary epithelial cells

Cancer Cell International

Volumn 5, Issue , 2005, Pages

  Zhang, Jiahui ^a   Tu, Yifan ^a   Smith Schneider, Sallie ^a  

^a BAYSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ESTROGEN; ESTROGEN RECEPTOR BETA; FENRETINIDE; PROGESTERONE; PROTEIN P21; PROTEIN P53; RETINOIC ACID; RETINOIC ACID RECEPTOR; TELOMERASE;

ARTICLE; BREAST CELL; BREAST EPITHELIUM; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

EID: 18144379187     PISSN: 14752867     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2867-5-6     Document Type: Article

References (44)

1. Rosner B, Colditz GA, Willett WC: Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol 1994, 139:819-35.
2. Kelsey JL, Gammon MD: The epidemiology of breast cancer. Ca-Cancer J Clin 1991, 41:146-65.
3. Sivaraman L, Conneely OM, Medina D, O'Malley BW: p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci USA 2001, 98:12379-84.
4. Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S: Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad Sci USA 1999, 96:2520-5.
5. Simeone AM, Tari AM: How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 2004, 61:1475-84.
6. Dragnev KH, Rigas JR, Dmitrovsky E: The retinoids and cancer prevention mechanisms. Oncologist 2000, 5:361-8.
7. Torrisi R, Decensi A, Formelli F, Camerini T, De Palo G: Chemoprevention of breast cancer with fenretinide. Drugs 2001, 61:909-18.
8. Band V, Zajchowski D, Kulesa V, Sager R: Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci USA 1990, 87:463-467.
9. ARF-p53 Pathway. Mol Cell Biol 2004, 24:2144-2152.
10. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955-959.
11. Bodnar AG, Ouellette M, Frolkins M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE: Extension of lifespan by introduction of telomerase into normal human cells. Science 1998, 279:349-352.
12. Formelli F, Camerini T, Cavadini E, Appierto V, Villani MG, Costa A, De Palo G, Di Mauro MG, Veronesi U: Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome. Cancer Epidemid Biomarkers 2003, 12: 34-41.
13. Rousseau C, Nichol JN, Pettersson F, Couture MC, Miller WH Jr: ER beta Sensitizes Breast Cancer Cells to Retinoic Acid: Evidence of Transcriptional Crosstalk. Mol Cancer Res 2004, 2: 523-31.
14. Zou A, Marschke KB, Arnold KE, Berger EM, Fitzgerald P, Mais DE, Allegretto EA: Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol Endocrinol 1999, 13:418-30.
15. Vogelstein B, Kinzler KW: Cancer Genes and the Pathways They Control. Nat Med 2004, 10:789-799.
16. Artandi SE: Complex roles for telomeres and telomerase in breast carcinogenesis. Breast Cancer Res 2003, 5:37-41.
17. Feldser DM, Hackett JA, Greider CW: Telomere Dysfunction and the Initiation of Genome Instability. Nat Rev Cancer 2003, 3:623-627.
18. Loveday RL, Greenman J, Drew PJ, Monson JR, Kerin MJ: Genetic changes associated with telomerase activity in breast cancer. Int J Cancer 1999, 84:516-20.
19. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H, Inoue M: Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 2000, 6:1239-47.
20. Stampfer MR, Garbe J, Nijjar T, Wigington D, Swisshelm K, Yaswen P: Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines. Oncogene 2003, 22:5238-51.
21. Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S: Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int J Cancer 2000, 88:733-6.
22. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H: Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001, 61:2537-41.
23. Leygue E, Dotzlaw H, Watson PH, Murphy LC: Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 1998, 58:3197-201.
24. Lange CA, Richer J, Horwitz KB: Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 1999, 13: 829-836.
25. Formby B, Willey TS: Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci 1998, 28:360-369.
26. Peck JD, Hulka BS, Poole C, Savitz DA, Baird D, Richardson BE: Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemid Biomarkers 2002, 11:361-8.
27. 1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ 1997, 8:631-641.
28. waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Cancer Res 1997, 57:2193-2199.
29. Zhang Y, Rishi AK, Dawson MI, Tschang R, Farhana L, Boyanapalli M, Reichert U, Shroot B, Van Buren EC, Fontana JA: S-phase Arrest and Apoptosis Induced in Normal Mammary Epithelial Cells by a Novel Retinoid. Cancer Res 2000, 60:2025-2032.
30. Mokbel K, Ghilchik M, Williams G, Akbar N, Parris C, Newbold R: The association between telomerase activity and hormone receptor status and p53 expression in breast cancer. Int J Surg Investig 2000, 1:509-16.
31. Brown T, Aldous W, Lance R, Blaser J, Baker T, Williard W: The association between telomerase, p53, and clinical staging in colorectal cancer. Am J Surg 1998, 175:364-6.
32. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995, 11:493-504.
33. Shah S, Pishvaian MJ, Easwaran V, Brown PH, Byers SW: The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Bio Chem 2002, 277:25313-22.
34. Adachi H, Adams A, Hughes FM, Zhang J, Cidlowski JA, Jetten AM: Induction of apoptosis by the novel retinoid AHPN in human T-cell lymphoma cells involves caspase-dependent and independent pathways. Cell Death Differ 1998, 5:973-983.
35. Li XH, Li H, Xiao ZJ, Piao YS: Divergent effects of retinoic acids on the expression of ERalpha and 17beta-hydroxysteroid dehydrogenase type 2 in endometrial carcinoma cells (RL 95-2). J Clin Endocr Metab 2002, 87:640-9.
36. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F: ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001, 142:4120-30.
37. Choi SH, Kang HK, Im EO, Kim YJ, Bae YT, Choi YH, Lee KH, Chung HY, Chang HK, Kim ND: Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by retinoic acids. Int J Oncol 2000, 17:971-6.
38. Lebeau J, Fouchet P, Ory K, Chevillard S: Down-regulation of telomerase activity after progesterone treatment of human breast cancer cells: essential role of the cell cycle status. Anticancer Res 2002, 22:2161-6.
39. Favoni RE, de Cupis A, Bruno S, Yee D, Ferrera A, Pirani P, Costa A, Decensi A: Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Brit J Cancer 1998, 77:2138-2147.
40. Herbert BS, Sanders BG, Kline K: N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells. Nutr Cancer 1999, 34:121-32.
41. Dokmanovic M, Chang BD, Fang J, Roninson IB: Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genes. Cancer Biol Ther 2002, 1:24-7.
42. Ciolino HP, Wang TT, Sathyamoorthy N: Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide. Brit J Cancer 2000, 83:333-7.
43. Simeone AM, Broemeling LD, Rosenblum J, Tari AM: HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. Oncogene 2003, 22:6739-47.
44. Rehman F, Shanmugasundaram P, Schrey MP: Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity. Brit J Cancer 2004, 91:1821-1828.